PDSB PDS BIOTECHNOLOGY CORP revenue, earnings and financials
For the quarter ended June 30, 2026, PDS BIOTECHNOLOGY CORP reported revenue of n/a, net income of −$9.75M and diluted EPS of −$0.18; for the fiscal year ended December 2025 revenue was n/a.
PDSB annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$31.5M, net income −$34.5M (margin n/a), EPS −$0.74
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$36.3M, net income −$37.6M (margin n/a), EPS −$1.03
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$43.0M, net income −$42.9M (margin n/a), EPS −$1.39
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$41.7M, net income −$40.9M (margin n/a), EPS −$1.43
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$21.4M, net income −$16.9M (margin n/a), EPS −$0.66
PDSB quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$9.75M, EPS −$0.18
- Quarter ended Mar 31, 2026: revenue n/a, net income −$7.35M, EPS −$0.13
- Quarter ended Dec 31, 2025: revenue n/a, net income −$7.56M, EPS −$0.13
- Quarter ended Sep 30, 2025: revenue n/a, net income −$9.01M, EPS −$0.19
- Quarter ended Jun 30, 2025: revenue n/a, net income −$9.43M, EPS −$0.21
- Quarter ended Mar 31, 2025: revenue n/a, net income −$8.49M, EPS −$0.21
- Quarter ended Dec 31, 2024: revenue n/a, net income −$7.95M, EPS −$0.21
- Quarter ended Sep 30, 2024: revenue n/a, net income −$10.7M, EPS −$0.29
- Quarter ended Jun 30, 2024: revenue n/a, net income −$8.33M, EPS −$0.23
- Quarter ended Mar 31, 2024: revenue n/a, net income −$10.6M, EPS −$0.30
- Quarter ended Dec 31, 2023: revenue n/a, net income −$10.9M, EPS −$0.35
- Quarter ended Sep 30, 2023: revenue n/a, net income −$10.8M, EPS −$0.35
- Quarter ended Jun 30, 2023: revenue n/a, net income −$11.5M, EPS −$0.37
- Quarter ended Mar 31, 2023: revenue n/a, net income −$9.66M, EPS −$0.32
- Quarter ended Dec 31, 2022: revenue n/a, net income −$19.1M, EPS −$0.65
- Quarter ended Sep 30, 2022: revenue n/a, net income −$7.42M, EPS −$0.26
- Quarter ended Jun 30, 2022: revenue n/a, net income −$5.82M, EPS −$0.20
- Quarter ended Mar 31, 2022: revenue n/a, net income −$8.47M, EPS −$0.32
- Quarter ended Dec 31, 2021: revenue n/a, net income −$6.32M, EPS −$0.25
- Quarter ended Sep 30, 2021: revenue n/a, net income −$6.96M, EPS −$0.24
PDSB cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$27.8M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$35.0M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$33.6M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$25.7M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$12.5M, share buybacks n/a
PDSB balance sheet
- Jun 30, 2026: cash $5.60M, total assets $8.81M, total liabilities $12.4M, shareholders' equity −$3.58M
- Mar 31, 2026: cash $21.7M, total assets $24.7M, total liabilities $20.8M, shareholders' equity $3.89M
- Dec 31, 2025: cash $26.7M, total assets $30.5M, total liabilities $21.2M, shareholders' equity $9.25M
- Sep 30, 2025: cash $26.2M, total assets $34.7M, total liabilities $25.3M, shareholders' equity $9.45M
- Jun 30, 2025: cash $31.9M, total assets $40.5M, total liabilities $24.5M, shareholders' equity $16.0M
- Mar 31, 2025: cash $40.0M, total assets $47.0M, total liabilities $24.7M, shareholders' equity $22.4M
- Dec 31, 2024: cash $41.7M, total assets $45.4M, total liabilities $26.4M, shareholders' equity $19.0M
- Sep 30, 2024: cash $49.8M, total assets $52.5M, total liabilities $30.4M, shareholders' equity $22.0M
Is PDSB profitable?
No. PDS BIOTECHNOLOGY CORP lost $33.7M over the last four quarters.
What is PDSB's EPS?
Diluted earnings per share over the last four quarters were −$0.63; −$0.18 in the latest quarter.